Should I buy Amgen (AMGN) stock or is it too late?

Amgen · Health Care · price $413

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: BMO Capital — 73% of its targets hit on this sector (240 calls tested). It aims for $415 (+0.5 %), call made on October 13, 2026, maturing on October 13, 2027 (1 d ago).

The 18 reliable analysts $395-4.5 %

The 4 other firms $435+5.4 %

How to read it: the 18 reliable firms are not filtered by optimism — 8 aim above the price, 10 below, hence their $395 median. “The 4 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Amgen

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Citigroup	100 %	+29.3 %	9	$405 -2%
Argus Research	78 %	+15.6 %	9	$460 +11%
Piper Sandler	74 %	+13.1 %	19	$457 +11%
Oppenheimer	67 %	+9.1 %	21	$450 +9%
Goldman Sachs	80 %	+8.1 %	5	$450 +9%
Morgan Stanley	57 %	+4.3 %	30	$359 -13%
RBC Capital	40 %	+3.8 %	10	$430 +4%
BMO Capital	38 %	+3.1 %	8	$415 +1%

In short — Should you invest in Amgen? Is it too late, still worth it? Analysts are split (36% buy, median target $420, i.e. +2%). We give you both sides, with the numbers — not advice.

✅ Reasons to believe

6 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
Pays a dividend (2.7% yield), raised for 14 years — regular income on top of potential upside.

⚠️ Reasons to hesitate

Even the most reliable firm on AMGN, Citigroup (100% hit rate, 9 scored calls), only targets $405 (call made on August 7, 2026, maturing on August 7, 2027) (-2%) in its most recent call. The stock may already have run past its target.
The consensus is not unanimous: of 22 ratings, 12 are neutral and 2 are sells.
Limited upside: the median target is only +2% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on AMGN

Median target $420 (+2%) · 22 ratings · Hold consensus

Strong Buy00%

Buy836%

Hold1255%

Sell29%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Amgen now?

We won't decide for you. The facts: 36% of analysts rate it a buy, median target $420 (+2%), and Citigroup (most reliable on AMGN, 100%) targets $405. Weigh that against valuation (P/E ~26). This is not personalized advice.

Is it too late to invest in Amgen?

The stated upside is small: the median target ($420) sits just +2% from the price ($413) (most reliable on AMGN: Citigroup, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Amgen still worth investing in?

It depends on the gap between the price ($413) and its estimated value: analysts target $420 on median (+2%), with 36% buys (most reliable on AMGN: Citigroup, 100%). Cross-check with their real reliability on AMGN and the cautions above. Information, not advice.

What's the main risk in buying AMGN?

Even the most reliable firm on AMGN, Citigroup (100% hit rate, 9 scored calls), only targets $405 (call made on August 7, 2026, maturing on August 7, 2027) (-2%) in its most recent call. The stock may already have run past its target.

→ Go deeper: the full Amgen profile (consensus, analyst reliability, price target, performance).